Curative Biotechnology Inc (CUBT) Prévision du cours des actions

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2001-07-11. The firm is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. The company has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The company is primarily focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its development pipeline is focused on three therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. IMT504 is an oligodeoxynucleotide (ODN). ODNs are synthetic molecules that stimulate different kinds of cells of immune system of animals and humans.